Potential radiation-sensitizing effect of semisynthetic epothilone B in human lung cancer cells

Radiotherapy and Oncology

Volumn 68, Issue 3, 2003, Pages 305-313

  Kim, Jae Chul ^a   Kim, Jae Sung ^a   Saha, Debabrata ^a   Cao, Qianwen ^a   Shyr, Yu ^a   Choy, Hak ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Epothilone B; Lung cancer; Radiation

Indexed keywords

DACTINOMYCIN; EPOTHILONE B; IXABEPILONE; PACLITAXEL; PROPIDIUM IODIDE; RADIOSENSITIZING AGENT; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; EPOTHILONE DERIVATIVE;

APOPTOSIS; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G2 PHASE; CONFERENCE PAPER; DRUG SCREENING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERMETHOD COMPARISON; NUDE MOUSE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; STAINING; TUMOR GROWTH; ANIMAL; ARTICLE; DOSE RESPONSE; DRUG EFFECT; FEMALE; LARGE CELL CARCINOMA; LUNG TUMOR; MOUSE; RADIATION EXPOSURE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, LARGE CELL; CELL CYCLE; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; EPOTHILONES; FEMALE; FLOW CYTOMETRY; HUMANS; INDICATORS AND REAGENTS; LUNG NEOPLASMS; MICE; MICE, NUDE; PACLITAXEL; PROPIDIUM; RADIATION-SENSITIZING AGENTS; TRANSPLANTATION, HETEROLOGOUS;

EID: 1542781317     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(03)00200-7     Document Type: Conference Paper

References (36)

1. Altmann K.H. Microtubule-stabilizing agents: a growing class of important anticancer drugs. Curr Opin Chem Biol. 5:2001;424-431.
2. Awada A., Bleiberg H., de Valeriola D., et al. Phase I clinical and pharmacology study of the epothilone analog BMS-247550 given weekly in patients with advanced solid tumors [abstract]. Proc Am Soc Clin Oncol. 20:2001;A268.
3. Bollag D.M., McQueney P.A., Zhu J., et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 55:1995;2325-2333.
4. Choy H., Rodriguez F.F., Koester S., Hilsenbeck S., Von Hoff D.D. Investigation of taxol as a potential radiation sensitizer. Cancer. 71:1993;3774-3778.
5. Colevas A.D., West P.J., Cheson B.D. Clinical trials referral resource. Current clinical trials of epothilone B analog (BMS-247550). Oncology (Huntingt). 15:(1168-1169):2001;1172-1175.
6. Cowden C.J., Paterson I. Synthetic chemistry. Cancer drugs better than taxol? Nature. 387:1997;238-239.
7. Damle B.D., Letrent S., Duncan G., et al. Pharmacokinetics (PK) and pharmacodynamics (PD) kineticsof BMS-247550, an epothilone analog, in patients with advanced solid tumors(abstract). Proc Am Soc Clin Oncol. 20:2001;A268.
8. Downing K.H. Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Annu Rev Cell Dev Biol. 16:2000;89-111.
9. Giannakakou P., Gussio R., Nogales E., et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci USA. 97:2000;2904-2909.
10. Hamel E. Antimitotic natural products and their interactions with tubulin. Med Res Rev. 16:1996;207-231.
11. Höfle G., Bedorf N., Steinmetz H., Schemburg D., Gerth K., Reichenbach H. Epothilone A and B - novel 16-membered macrolides with cytotoxic activity: isolation, crystal structure, and conformation in solution. Angew Chem Int Ed Engl. 35:1996;1567-1569.
12. Kim J.S., Amorino G.P., Pyo H., Cao Q., Price J.O., Choy H. The novel taxane analogs, BMS-184476 and BMS-188797, potentiate the effects of radiation therapy in vitro and in vivo against human lung cancer cells. Int J Radiat Oncol Biol Phys. 51:2001;525-534.
13. Kowalski R.J., Giannakakou P., Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)). J Biol Chem. 272:1997;2534-2541.
14. Krishan A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol. 66:1975;188-193.
15. Kurdoglu B., Cheong N., Guan J., Corn B.W., Curran W.J. Jr, Iliakis G. Apoptosis as a predictor of paclitaxel-induced radiosensitization in human tumor cell lines. Clin Cancer Res. 5:1999;2580-2587.
16. Lee F.Y.F., Vite G., Borzilleri R., et al. Preclinical pharmacology of the epothilone B analog BMS-247550 - an epothilone analog possessing potent activity against paclitaxel-sensitive and -resistant human tumors. Clin Cancer Res. 6:(Suppl):2000;4580s.
17. Lee F.Y.F., Borzilleri R., Fairchild C.R., et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res. 7:2001;1429-1437.
18. Liebmann J., Cook J.A., Fisher J., Teague D., Mitchell J.B. In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst. 86:1994;441-446.
19. LoRusso P.M., Wozniak A.J., Flaherty L.E., Shields A.F., Wright J., Lebwohl D. Phase I clinical trial of BMS-247550 (epothilone B analog; NSC #710428) in adult patients with advanced solid tumors [abstract]. Proc Am Soc Clin Oncol. 20:2001;A2125.
20. Mani S., McDaid H., Shen H.-J. Phase I evaluation of an epothilone B analog (BMS-247550): clinical findings and molecular correlates [abstract]. Proc Am Soc Clin Oncol. 20:2001;A269.
21. Milas L., Hunter N.R., Mason K.A., Milross C.G., Saito Y., Peters L.J. Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res. 55:1995;3564-3568.
22. Milas L., Saito Y., Hunter N., Milross C.G., Mason K.A. Therapeutic potential of paclitaxel-radiation treatment of a murine ovarian carcinoma. Radiother Oncol. 40:1996;163-170.
23. Milas L., Milas M.M., Mason K.A. Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol. 9:1999;12-26.
24. Milross C.G., Mason K.A., Hunter N.R., et al. Enhanced radioresponse of paclitaxel-sensitive and -resistant tumours in vivo. Eur J Cancer. 33:1997;1299-1308.
25. Muhlradt P.F., Sasse F. Epothilone B stabilizes microtubuli of macrophages like taxol without showing taxol-like endotoxin activity. Cancer Res. 57:1997;3344-3346.
26. Schiff P.B., Fant J., Horwitz S.B. Promotion of microtubule assembly in vitro by taxol. Nature. 277:1979;665-667.
27. Service R.F. Tumor-killer made; how does it work? Science. 274:1996;2009.
28. Sinclair W.K., Morton R.A. X-ray and ultraviolet sensitivity of synchronized Chinese hamster cells at various stages of the cell cycle. Biophys J. 5:1965;1-25.
29. Sinclair W.K., Morton R.A. X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res. 29:1966;450-474.
30. Spriggs D., Soignet S., Bienvenu B., Letrent S., Lebwohl D., Burris H. Phase I and pharmacology study of the epothilone B analog BMS-247550 in patients with advanced cancer [abstract]. Proceedings of the 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy. Clin Cancer Res. 6:(Suppl):2000;A574.
31. Spriggs D., Soignet S., Bienvenu B., et al. Phase I first-in-man study of the epothilone B analog BMS-247550 in patients with advanced cancer [abstract]. Proc Am Soc Clin Oncol. 20:2001;A428.
32. Steel G.G., Peckham M.J. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys. 5:1979;85-91.
33. Steren A., Sevin B.U., Perras J., et al. Taxol as a radiation sensitizer: a flow cytometric study. Gynecol Oncol. 50:1993;89-93.
34. Steren A., Sevin B.U., Perras J., et al. Taxol sensitizes human ovarian cancer cells to radiation. Gynecol Oncol. 48:1993;252-258.
35. Walczak C.E. Microtubule dynamics and tubulin interacting proteins. Curr Opin Cell Biol. 12:2000;52-56.
36. Yamaguchi H., Paranawithana S.R., Lee M.W., Huang Z., Bhalla K.N., Wang H.G. Epothilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells. Cancer Res. 62:2002;466-471.